English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the discovery of the natriuretic peptides in the 1980s and their subsequent introduction into clinical laboratory testing in the 2000s, assays of B-type natriuretic peptides (BNPs)1 have gained widespread acceptance as important tools for diagnosis and risk stratification in the acute-care setting. Tests for natriuretic peptides accurately diagnose heart failure in patients presenting to emergency rooms with dyspnea (1)(2) and stratify risk in patients presenting with unstable angina or acute myocardial infarction. In some studies of stable patients, natriuretic peptides have shown strong associations with cardiovascular events, raising the possibility that their use as a screening tool in asymptomatic patients may help clinicians prevent heart attack and stroke. Such a finding would have enormous public health implications and would likely lead to a vast expansion in the use of these diagnostic markers and a shift from the acute-care setting to the outpatient clinic. Therefore, what we do and do not know about natriuretic peptides as predictors of cardiovascular events in stable patients is of considerable interest to clinicians, clinical chemists, and the manufacturers and marketers of the diagnostic tests. To address these issues and to make comparing studies more straightforward, Di Angelantonio and colleagues systematically assessed the relationship between natriuretic peptide concentrations and cardiovascular events in studies of populations that represented a wide range of baseline cardiovascular risk (3). Their recently published metaanalysis is the subject of this perspective.Di Angelantonio and colleagues analyzed results from 40 studies that included 87 474 participants and 10 625 cardiovascular events. Of these events, the largest number (n = 7314) was observed in populations with preexisting cardiovascular disease (CVD); fewer events were observed among those with increased markers of CVD risk (n = 2040) and among …

B-Type Natriuretic Peptides and the Promise of Improved Cardiovascular Risk Prediction